Longevity and Vielight Technology | Published Clinical Trials

The Mitochondrial "Sweet Spot": The 810nm Wavelength

Not all light is created equal. When it comes to restoring mitochondrial function in the brain, precision matters.

In the world of brain photobiomodulation (PBM), there is an ongoing debate between using 810nm (near-infrared) versus longer wavelengths like 1064nm or 1070nm. While both have their proponents, the science points to 810nm as the superior choice for mitochondrial restoration.

Here is why 810nm wins the longevity argument:

• Cytochrome C Oxidase (CCO) Peak: CCO is the enzyme inside mitochondria that accepts photons to boost energy production. Its absorption peaks near 810nm, making this wavelength the “mitochondrial sweet spot” for efficient ATP production.

• Avoiding Water Absorption: Longer wavelengths like 1064nm and 1070nm face a significant hurdle – water. The human body (and brain) is abundant in water, which absorbs light heavily above 1000nm. This means less energy reaches your brain cells compared to 810nm, which passes through water with far less resistance.

• Mechanism of Action: While 1064nm primarily affects heat-sensitive ion channels (a more experimental pathway), 810nm directly engages the mitochondrial respiratory chain. For consistent, proven neuroprotective benefits, 810nm remains the gold standard supported by the most published research.

Vielight Intranasal-Transcranial Dual Pathway Delivery (itPBM)

The human skull is a highly effective evolutionary barrier. To deliver therapeutic energy to a living brain, a device must solve two problems: penetrating dense bone from the outside, and reaching deep-brain hubs on the inside. Vielight achieves this through two parallel, industry-leading innovations:

1. Industry-Leading Transcranial Irradiance: Our patented transcranial Vie-LED technology is engineered specifically to overcome the heavy cranial bone barrier. By maximizing power density (mW/cm²), it delivers the industry’s highest non-thermal irradiance, forcing near-infrared light deep into the brain’s superior networks.

2. The Intranasal Anatomical Shortcut: Operating in tandem with the Vie-LEDs, our intranasal channel targets the underside of the brain via the cribriform plate. Measuring a mere 0.1 mm thick, this porous pathway allows light to bypass thick bone completely, flooding deep brain structures and circulating blood cells with energy.

Together, this unified system is known as intranasal-transcranial photobiomodulation technology, or itPBM. This unparalleled coverage advantage is precisely why Vielight leads the industry in the total volume of published clinical trials, setting the global standard for neuroimaging and cognitive performance validation.

[Transcranial Vie-LEDs]  --> Targets Cortical Surfaces
         +                                                      
[Intranasal Applicator]  --> Deep Brain Structures 
--------------------------------------------------------
=                     Unparalleled 360° Coverage (itPBM)

Clinical Evidence for Longevity: Vielight Enhances Neural Mitochondria

The Vielight Neuro is backed by rigorous clinical research. Here are a few key studies with the Vielight Neuro linked to mitochondrial longevity and cognition:

1. Reversing Mitochondrial Dysfunction in MCI (2026): A 20-participant, single-blind, sham-controlled pilot trial at the University of Toronto (St. Michael’s Hospital) evaluated the Vielight Neuro in adults with Mild Cognitive Impairment. Over six weeks, the active group showed greater improvement than sham in global cognition (MMSE) and episodic memory, alongside blood-marker changes consistent with improved mitochondrial efficiency and a reduction in the inflammatory marker IL-6.

2. Significant Cognitive Gains in TBI (2024/2025): Multiple studies from the University of Utah report that the Vielight Neuro Gamma was associated with improvements in executive function, reaction time, and balance in individuals with traumatic brain injury, brain network connectivity.

3. Dementia Pilot Success (2015): In a landmark clinical trial, participants with dementia using Vielight technology showed improvements in cognitive and behavioral measures, with fMRI indicating increased functional connectivity in the brain’s Default Mode Network.

4. Combatting “Brain Fog” & Neuroinflammation (Long COVID): A randomized, double-blind clinical trial (n=43) examined post-COVID “brain fog” using the Vielight Neuro Gamma. Participants, particularly those under 45,  showed improvements in cognitive scores and attention tasks over eight weeks of home use, with the authors discussing reduced neuroinflammation as a candidate mechanism.
5. Neuroprotection in Parkinson’s Disease. An n=14 proof-of-concept study in idiopathic Parkinson’s disease examined the Vielight Neuro over 12 weeks. Participants reported improvements in mobility, fine motor skills, and cognition, with gains the authors observed to persist over the follow-up period. The authors describe these findings as preliminary.
6. “Tuning” the Brain: The Gamma Effect: Published in Nature Scientific Reports (2019), this pivotal study found that a single 20-minute session with the Vielight Neuro Gamma was associated with increased high-frequency oscillations (alpha, beta, gamma) and reduced slow-wave activity (delta, theta) — a shift in the brain’s electrical signature toward a more activated state.

Systemic Health (Verified by a Major Clinical Trial)

While brain longevity is the ultimate goal, your brain does not exist in a vacuum. It relies on a healthy body, robust circulation, and a resilient immune system to function at its peak. This is where Vielight’s technology offers a distinct advantage through Systemic Photobiomodulation (PBM).

Vielight devices like the RX Plus don’t just target localized tissue; they utilize the dense capillary network inside the nasal cavity to irradiate the blood circulating through the entire body.

The Evidence: The World’s Largest Successful PBM Trial

The power of this systemic approach was proven in a major, peer-reviewed clinical trial involving 294 participants—the largest of its kind ever conducted in the field of photobiomodulation.

• The Challenge: The study focused on accelerating recovery from acute respiratory viral infections (specifically COVID-19) in patients experiencing moderate-to-severe symptoms.

• The Result: Participants who used the Vielight device within the first 7 days of symptoms recovered significantly faster than those who received standard care alone. The therapy effectively reduced respiratory symptoms, headaches, and body aches.

• The Mitochondrial Mechanism: When near-infrared light irradiates the bloodstream intranasally, it directly targets the mitochondria inside circulating white blood cells and blood platelets. By optimizing mitochondrial respiration and ATP output within these moving immune cells, PBM safely downregulates the overproduction of pro-inflammatory cytokines—the molecules responsible for systemic inflammation.

Why This Matters for Longevity:

This landmark trial led to the Vielight RX Plus receiving a Medical Device License from Health Canada for accelerating recovery from respiratory viral infections.

For the longevity-focused individual, this validates that intranasal light therapy triggers a potent, body-wide biological response. Chronic, low-grade systemic inflammation—often termed “inflammaging”—is heavily driven by progressive mitochondrial decay and dysfunction. By optimizing cellular energy in the bloodstream and cooling systemic inflammation, you create a cleaner, high-functioning physiological environment for your brain to thrive.